SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
84 hedge funds and large institutions have $1.98B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 41 increasing their positions, 23 reducing their positions, and 19 closing their positions.
318% more call options, than puts
Call options by funds: $6.14M | Put options by funds: $1.47M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 23
3% more capital invested
Capital invested by funds: $1.92B → $1.98B (+$65.2M)
12% less funds holding
Funds holding: 95 → 84 (-11)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$15.9M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$14.8M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$8.56M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.78M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$7.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$16.9M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$11.6M |
| 3 |
PC
PointState Capital
New York
|
-$10.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.75M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
101
Tower Research Capital (TRC)
New York
| – | -$148K | -2,337 | Closed |
|
102
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$28K | -435 | Closed |
|
|
SSG
103
Summit Securities Group
New York
| – | -$6K | -100 | Closed |
|
GEVA Hedge Fund Activity: Q4 2013 in Review
84 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q4 2013, worth a combined $1.98B — up 3.4% from $1.92B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of GEVA and 8 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 41 added.
The largest buyer was Sectoral Asset Management, adding an estimated $15.9M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $16.9M sold.
- 84 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q4 2013, down from 95 in Q3 2013.
- Funds reported $1.98B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q4 2013, up 3.4% quarter-over-quarter.
- 8 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q4 2013 and 19 closed out, a net change of -11 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q4 2013 was Sectoral Asset Management, an estimated $15.9M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q4 2013 was Bain Capital Public Equity Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2013.